Resumen de: US2023056702A1

The present disclosure is directed towards a method of treating a disease or condition associated with gut inflammation. The present disclosure comprises administering, to a patient in need thereof, a composition comprising oxygen-scavenging membrane fragments or membrane vesicles. In some embodiments, membrane vesicles are derived from bacteria. In some embodiments, membrane vesicles are derived from the cytoplasmic membranes of Escherichia coli, Salmonella typhimurium, Gluconobacter oxydans, Pseudomonas aeruginosa, or Acetobacter.

Resumen de: WO2021240110A1

The invention relates to a sensor (100) comprising: - a prism (110) that comprises a first face (111); - a metal first layer (120) covering, via a contact face (121), the first face (111) - a light source (130); and - a matrix-array detector (140); the device comprises a dielectric second layer (160) on which rests a transistor (150) that comprises a sheet (151), made of a two-dimensional material, intended to form a channel region, a front face (154) of the sheet comprising a specific functionalisation (155) via which specific targets are liable to be adsorbed, the specific functionalisation (155) being suitable for placing the adsorbed specific targets at a smaller distance Dd below which detection via electrical measurement by means of the specific transistor (150) and via measurement of resonance of surface plasmons is possible.

Resumen de: WO2023015810A1

Provided in the present invention are an InDel molecular marker of ultrasonic mutagenesis salmonella typhimurium hisD gene and the use thereof, which belong to the field of molecular biology. In the present invention, it is found by means of ultrasonically inducing salmonella typhimurium and sequencing same that all InDel mutations occur in a core mutation region of the hisD gene. Therefore, the core mutation region is used as the InDel molecular marker and is used for analyzing the determination of an insertion or deletion type of a gene reverse mutation. Moreover, the InDel molecular marker also can be used to analyze the relationship between the hisD gene sequence and the function of a protein encoded thereby.

Resumen de: WO2021115410A1

Provided is an immunostimulatory composition, comprising saponin and CpG oligodeoxynucleotides or composed of a saponin-containing adjuvant and CpG oligodeoxynucleotides, wherein a CpG oligodeoxynucleotide sequence has two or more copies of 5'-TTCGTT-3' motif or 5'-TCGTCGTCG-3' motif. Also provided is use of the immunostimulatory composition in the preparation of a drug for treating diseases.

Resumen de: US2018100159A1

This disclosure provides intact bacterially derived minicells containing nucleic acids adjuvants or plasmids encoding nucleic acids adjuvants that can produce a desired immune response in target cells. This disclosure further provides methods that employ minicells to deliver nucleic acids adjuvants for use in the treatment of diseases, including neoplastic disease and cancer.

Resumen de: WO2023003329A1

The present invention relates to a vaccine composition comprising a capsular polysaccharide-protein conjugate derived from Salmonella typhi, wherein the optimal culture conditions for Salmonella typhi growth and Vi capsular polysaccharide expression were established, the purified Vi capsular polysaccharide was conjugated to a conjugate protein to produce a conjugate having a specific average molecular weight, and it was confirmed that a Vi capsular polysaccharide-conjugated protein conjugate of the present invention had excellent immunogenicity. A method for producing the Vi capsular polysaccharide-conjugated protein conjugate of the present invention, and a conjugate produced thereby can be used for the prevention of typhoid.

Resumen de: WO2018167290A1

The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding PD-L1. In particular, the present invention relates to said attenuated strain of Salmonella for use in the treatment of cancer.

Resumen de: US2023041880A1

This disclosure relates to a method for sanitizing a space. The method includes applying a composition containing triethylene glycol into a space containing a pathogen (e.g., a Staphylococcus, a Pseudomonas, a Listeria, Salmonella, Klebsiella, a Mycobacterium, a mold, or a spore) in an amount effective to inactivate the pathogen.

Resumen de: WO2021198376A1

The present invention relates to a DNA vaccine comprising a Salmonella typhi Ty21a strain comprising a DNA molecule comprising a eukaryotic expression cassette encoding at least a COVID-19 coronavirus (SARS-CoV-2) spike (S) protein or a portion thereof. In particular, the present invention relates to the DNA vaccine for use in the prevention and/ or the treatment of coronavirus disease 2019 (COVID-19) or a SARS-CoV-2 infection.

Resumen de: WO2021189226A1

A method of taking a skin sample can include placing an adhesive onto a portion of skin and lifting the adhesive from the skin. A skin sample may then be tested while still on the adhesive, for example, by inoculating the sample with a bacterium, fungus, virus, or a combination.

Resumen de: WO2021202630A2

The present disclosure is directed to genetically modified bacteria that produce a diffusible signal factor (DSF). The disclosure also provides methods for treating or preventing Salmonella infection/invasion in a subject. The disclosure further provides vectors and compositions for carrying out the methods disclosed herein.

Resumen de: WO2023007456A1

The object of the invention is a method for producing bacterial lipopolysaccharide (LPS)/protein immune complexes, the use of the LPS/protein complex to induce an immune response, a method for producing a veterinary vaccine comprising the LPS/protein immune complex and a veterinary vaccine produced by this method.

Resumen de: WO2021255684A1

A composition comprising Shigella-Tetravalent (4-valent Shigella) bioconjugates. That encompasses the Shigella O-polysaccharide antigens of serotypes Shigella flexneri 2a, 3a, 6 and Shigella sonnei covalently linked to the protein carrier.

Resumen de: WO2023009213A1

This disclosure relates to a method for sanitizing a space. The method includes applying a composition containing triethylene glycol into a space containing a pathogen (e.g., a Staphylococcus, a Pseudomonas, a Listeria, Salmonella, Klebsiella, a mycobacterium, a mold, or a spore) in an amount effective to inactivate the pathogen.

Resumen de: AU2020454144A1

The present invention relates to a Salmonella strain that selectively acts on cancer for the treatment of cancer, and a composition for preventing or treating cancer comprising same. Specifically, the Salmonella strain according to the present invention has a tumor-suppressing effect, but the viability thereof is significantly low in normal organs, and thus can have a significant anticancer effect compared to the conventional invention.

Resumen de: AU2021291618A1

The present invention provides for a modified autotransporter and the use of genetically engineered microorganisms comprising said modified autotransporters in the treatment of infectious and neoplastic disease. The present invention therefore also relates to vaccine and immunotherapeutic compositions comprising said genetically engineered microorganism.

Resumen de: WO2023007456A1

The object of the invention is a method for producing bacterial lipopolysaccharide (LPS)/protein immune complexes, the use of the LPS/protein complex to induce an immune response, a method for producing a veterinary vaccine comprising the LPS/protein immune complex and a veterinary vaccine produced by this method.

Resumen de: AU2022283757A1

Sampling systems that include an absorbent material a preservative, such as an analyte preservative, as well as related materials and methods, are disclosed.

Resumen de: WO2023010008A1

Compositions, methods, kits, and uses are provided for detecting the presence of Salmonella, Shigella, Campylobacter, and Shigatoxigenic Eschelichia coli (STEC) in samples. In some embodiments, the compositions, methods, kits, and uses comprise one or more oligonucleotides or the use of one or more oligonucleotides. In some embodiments, the method is carried out as a multiplex assay with separate primers/probes for C.jejuni and C.coli. Some of the oligonucleotides contain inosine and/or contain 5-methylcytosine substituted nucleotides. Described is the use of cyclodextrin and/or Polysorbate 20 in the amplification reactions.

Resumen de: WO2023006879A1

The present invention relates to the field of cancer therapy. In particular, the present invention relates to a first composition comprising a live attenuated bacterium for use in the treatment, prevention, reduction, inhibition, prevention of recurrence, or control of a neoplastic disease in a subject being or intended to be administered a second composition comprising a live attenuated bacterium, said bacterium being the same or different to that of the first composition and methods thereof.

Resumen de: EP4124342A1

The present invention relates to the field of cancer therapy. In particular, the present invention relates to a method of preventing, treating or inhibiting the development of neoplastic disease in a subject.

Resumen de: WO2021044436A2

The present disclosure relates to novel immunogenic monovalent and multivalent polysaccharide-protein conjugate vaccine compositions comprising a polysaccharide selected from Salmonella serovar strains S. typhi; S. paratyphi A; S. typhimurium and S. enteritidis and alternative improved methods of polysaccharide fermentation, polysaccharide purification, polysaccharide-protein conjugation and stable formulation. The present disclosure further relates to methods for inducing an immune response in subjects against Salmonella typhi and non-typhi related diseases and/or for reducing or preventing Salmonella typhi and non-typhi related diseases in subjects using the compositions disclosed herein. The vaccine elicits bactericidal antibodies and is useful for prevention of gastroenteritis, enteric and typhoid fever.

Resumen de: WO2023003329A1

The present invention relates to a vaccine composition comprising a capsular polysaccharide-protein conjugate derived from Salmonella typhi, wherein the optimal culture conditions for Salmonella typhi growth and Vi capsular polysaccharide expression were established, the purified Vi capsular polysaccharide was conjugated to a conjugate protein to produce a conjugate having a specific average molecular weight, and it was confirmed that a Vi capsular polysaccharide-conjugated protein conjugate of the present invention had excellent immunogenicity. A method for producing the Vi capsular polysaccharide-conjugated protein conjugate of the present invention, and a conjugate produced thereby can be used for the prevention of typhoid.

Resumen de: WO2023002252A1

The present invention relates to a composition and methods comprising an amount of β-glucans and α-fucans, wherein the combination is synergistic to at least one of: increase growth of beneficial microbes and reduced levels of harmful microbes selected from E. coli or Salmonella in animal or human intestines, improve gut structure, reduce gut inflammation, improved nutrient digestibility, improve mineral absorption and growth performance, or reduce gut infection and inflammation.

Resumen de: US2023029322A1

The invention relates to the field of medical diagnosis, particularly to methods and antibodies useful for the identification of colibactin producing bacteria (pks+ bacteria). Herein are disclosed peptides and antibodies that allow for the detection and isolation of pks+ bacteria, as well as uses and methods of use of said peptides and antibodies.